FridrichMethod Molecular Glue Discovery Agent
The Molecular Glue Discovery Agent enables AI-driven discovery of molecular glue degraders that induce protein-protein interactions between E3 ligases and neo-substrates for targeted protein degradation. Unlike PROTACs, molecular glues are smaller, more drug-like molecules that can access previously "undruggable" targets through induced proximity mechanisms.
When to Use This Skill
- When discovering new molecular glue scaffolds.
- For identifying neo-substrate targets for existing glues.
- To design glues for specific E3-substrate pairs.
- When optimizing glue selectivity and potency.
- For virtual screening of glue candidates.
Core Capabilities
Glue Scaffold Discovery: Identify novel molecular glue chemotypes.
Neo-Substrate Prediction: Predict proteins degraded by glues.
Interface Modeling: Model E3-glue-substrate ternary interfaces.
Selectivity Optimization: Design for specific substrate profiles.
SAR Analysis: Structure-activity relationship modeling.
Virtual Screening: Screen compounds for glue activity.
Molecular Glue Mechanisms
| Class | E3 Ligase | Mechanism | Example |
|---|---|---|---|
| IMiDs | CRBN | Degron recognition | Lenalidomide |
| CELMoDs | CRBN | Enhanced IKZF binding | Iberdomide |
| DCAF15 Glues | DCAF15 | Splicing factor degradation | Indisulam |
| CDK12 Glues | DDB1-CRBN | Cyclin K degradation | CR8 derivatives |
| β-catenin Glues | Novel | WNT pathway targets | Emerging |
Key Neo-Substrates
| Substrate | Glue Class | Disease Relevance |
|---|---|---|
| IKZF1/3 | IMiDs | Multiple myeloma |
| CK1α | Lenalidomide | MDS del(5q) |
| GSPT1 | CC-885 | AML |
| RBM39 | Indisulam | Solid tumors |
| Cyclin K | CR8 | Cancer |
| SALL4 | Thalidomide | Teratogenicity |
Workflow
Input: Target substrate, E3 ligase, screening library.
Interface Analysis: Model E3 surface and potential binding sites.
Virtual Screening: Screen compounds for interface binding.
Glue Scoring: Predict neo-substrate recruitment potential.
Selectivity Analysis: Predict off-target degradation.
Optimization: Iterative design for potency/selectivity.
Output: Ranked glue candidates with predicted profiles.
Example Usage
User: "Discover molecular glues that degrade IKZF1 through CRBN with improved selectivity over IKZF3."
Agent Action:
python3 Skills/Drug_Discovery/Molecular_Glue_Discovery_Agent/discover_glue.py \
--target_substrate IKZF1 \
--e3_ligase CRBN \
--selectivity_against IKZF3 \
--scaffold_library imid_derivatives.sdf \
--interface_model crbn_ikzf1_complex.pdb \
--n_candidates 100 \
--output glue_discovery/
Glue Design Parameters
| Parameter | Consideration | Optimization |
|---|---|---|
| Interface Complementarity | E3-substrate fit | Shape/electrostatics |
| Degron Recognition | Substrate degron motifs | Motif compatibility |
| Binding Cooperativity | Positive cooperativity | Enhanced ternary |
| Selectivity | Off-target degradation | Substrate specificity |
| Drug Properties | MW, solubility, permeability | Standard optimization |
Output Components
| Output | Description | Format |
|---|---|---|
| Glue Candidates | Ranked molecules | .sdf, SMILES |
| Predicted Substrates | Neo-substrate profiles | .csv |
| Interface Models | Ternary complex structures | .pdb |
| Selectivity Scores | On-target vs off-target | .csv |
| Degradation Predictions | DC50, Dmax estimates | .csv |
| SAR Analysis | Structure-activity trends | .json |
AI/ML Components
Interface Prediction:
- Protein-protein docking
- Molecular surface analysis
- Deep learning interface scoring
Neo-Substrate Discovery:
- Degron motif prediction
- Proteome-wide screening
- Structural similarity to known substrates
Glue Optimization:
- Generative chemistry
- Multi-objective optimization
- Active learning for synthesis prioritization
Glue vs PROTAC Comparison
| Feature | Molecular Glue | PROTAC |
|---|---|---|
| Molecular Weight | <500 Da | 700-1500 Da |
| Target Discovery | Serendipitous/AI | Rational |
| Selectivity | Can be exquisite | Often broader |
| Substrate Range | Induced neo-substrates | Direct binders |
| Oral Bioavailability | Generally better | Challenging |
Clinical Pipeline (2026)
| Drug | Mechanism | Target | Phase |
|---|---|---|---|
| Iberdomide (CC-220) | CELMoD | IKZF1/3, Aiolos | Phase 3 |
| Mezigdomide (CC-92480) | CELMoD | IKZF1/3 | Phase 3 |
| Golcadomide (CC-99282) | CELMoD | IKZF1/3 | Phase 2 |
| CFT7455 | IKZF1/3 | IKZF1/3 | Phase 1 |
Degron Motif Analysis
| Degron Type | Sequence Features | E3 Recognition |
|---|---|---|
| Zinc Finger | C2H2 ZF domain | CRBN-IMiD |
| Phosphodegron | pSer/pThr motifs | SCF E3s |
| N-degron | N-terminal residues | UBR1/2 |
| Hydrophobic | Exposed hydrophobics | Quality control |
Prerequisites
- Python 3.10+
- RDKit, Molecular modeling tools
- AlphaFold2/3, docking software
- Deep learning frameworks
- Protein structure databases
Related Skills
- PROTAC_Design_Agent - Bifunctional degraders
- TPD_Ternary_Complex_Agent - Complex modeling
- Virtual_Screening_Agent - High-throughput screening
- Protein_Protein_Docking_Agent - PPI modeling
Discovery Strategies
| Strategy | Approach | Success Examples |
|---|---|---|
| Phenotypic Screening | Degradation readout | IMiDs, indisulam |
| Target-Based | E3-substrate docking | Rational glues |
| Chemoproteomics | Pull-down identification | Neo-substrate discovery |
| AI-Guided | Computational prediction | Emerging |
Special Considerations
- Polypharmacology: Glues often degrade multiple substrates
- Species Differences: Neo-substrates may differ across species
- Resistance: Substrate mutations, E3 downregulation
- Toxicity: Off-target degradation (e.g., SALL4)
- Hook Effect: Less common than PROTACs
Quality Control
| Metric | Purpose | Threshold |
|---|---|---|
| Interface Score | Complex stability | >0.6 |
| Cooperativity | Enhanced binding | >1.5 |
| Selectivity Index | On/off-target ratio | >10 |
| Drug-likeness | Developability | Lipinski compliant |
Future Directions
| Direction | Status | Potential |
|---|---|---|
| New E3 Ligases | Active research | Expanded target space |
| Protein-Protein Glues | Emerging | Beyond degradation |
| AI-First Discovery | Advancing | Reduced serendipity |
| Combination Glues | Conceptual | Multi-target degradation |
Author
AI Group - Biomedical AI Platform